Cancer diagnosis, treatment selection and treatment

• US 10,308,986 B2
• Filed: 03/13/2014
• Issued: 06/04/2019
• Est. Priority Date: 03/14/2013
• Status: Active Grant

• Current Assignee: Brigham and Women's Hospital Incorporated, Children's Medical Center Corporation, Dana-Farber Cancer Institute
• Original Assignee: Brigham and Women's Hospital Incorporated, Children's Medical Center Corporation, Dana-Farber Cancer Institute, Technical University of Denmark
• Inventors: Szallasi, Zoltan I., Richardson, Andrea L., Birkbak, Nicolai J., Wang, Zhigang
• Primary Examiner(s): Bredefeld, Rachael E
• Assistant Examiner(s): Simmons, Chris E
• Application Number:
  US14/774,772
• Publication Number:
  US 20160122827A1
• Time in Patent Office: 1,909 Days
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 33/57415 of breast

Abstract

The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell expression profile.

Claims

1. A method for treating cancer having increased expression of BLM and FANCI of at least two-fold compared to BRCA1 expression in a human subject in need thereof, said method comprising the step of administering a platinum-comprising cancer chemotherapy to the human subject.

2. A method of treating cancer having cancer cells with a chromosome 15q26 copy number gain compared to the cancer cells'"'"' chromosome 15centromere copy number in a human subject in need thereof, said method comprising the step of administering a platinum-comprising cancer chemotherapy to the human subject.

3. The method of claim 2, wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer.

4. The method of claim 2, wherein the subject'"'"'s cancer is known to not express a detectable quantity of ER, PgR, and HER2 receptor.